Structure Therapeutics (NASDAQ:GPCR) Shares Up 10.9% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) rose 10.9% on Wednesday . The company traded as high as $43.00 and last traded at $44.79. 202,690 shares were traded during trading, a decline of 77% from the average daily volume of 884,261 shares. The stock had previously closed at $40.38.

Trending Headlines about Structure Therapeutics

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: Citizens JMP reaffirmed its “Market Outperform” rating and set a $110 price target, implying substantial upside from recent trading levels. The bullish view reflects the potential of Structure’s oral obesity-treatment pipeline. Benzinga analyst rating report
• Positive Sentiment: Structure reported encouraging clinical updates for its oral small-molecule programs. Aleniglipron, an oral GLP-1 agonist, produced up to a 16.2% mean reduction in body weight at 72 weeks, with no observed plateau and fewer than 5% of patients discontinuing because of adverse events in the ACCESS open-label extension study. Structure Therapeutics clinical data release
• Positive Sentiment: The company’s oral amylin candidate ACCG-2671 showed a roughly six-day half-life, evidence of target engagement and up to 3.3% body-weight loss in an early Phase 1/2a study, with no serious adverse events reported. The multiple-dose portion has begun, although results are not expected until the first half of 2027. RTTNews clinical data report
• Neutral Sentiment: Phase 3 enrollment for aleniglipron is continuing, but topline results are not expected until the second half of 2028. This leaves significant execution and clinical-development risk before potential commercialization. Seeking Alpha conference-call transcript
• Negative Sentiment: Despite the positive headline data, the stock declined in reaction to the obesity-drug update, suggesting investors may have viewed the results as insufficiently differentiated or focused on the early-stage status and lengthy timeline of the programs. Seeking Alpha market reaction report

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday, August 7th. Citizens Jmp reissued a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday. Finally, Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Price Performance

The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -43.18 and a beta of -1.45. The stock has a 50 day moving average price of $50.41 and a two-hundred day moving average price of $49.01.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GPCR. Morgan Stanley increased its stake in Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares during the period. Wellington Management Group LLP boosted its position in Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after buying an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Structure Therapeutics by 477.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after acquiring an additional 1,381,745 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after acquiring an additional 1,150,000 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC acquired a new position in shares of Structure Therapeutics in the fourth quarter worth $61,086,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.